{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:08:10Z","timestamp":1789427290668,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immunochemotherapy (nICT) has emerged as a promising strategy for patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC), yet real-world evidence comparing its efficacy and safety with conventional neoadjuvant chemotherapy (nCT) remains scarce. Furthermore, the underlying immune microenvironment dynamics associated with these clinical benefits have not been fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of patients with resectable LA-ESCC who received either nICT or nCT followed by curative esophagectomy. We used inverse probability of treatment weighting (IPTW) to minimize selection bias. The primary endpoints were overall survival (OS) and disease-free survival (DFS). In addition, we analyzed recurrence patterns and performed multiplex immunohistochemistry (mIHC) to characterize the immune microenvironment associated with treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 224 patients received nICT and 80 received nCT. After IPTW adjustment, OS in the nICT group was significantly better than in the nCT group (3-year OS: 77.68%\n                      <jats:italic>vs<\/jats:italic>\n                      . 67.49%; HR = 0.61, 95% CI: 0.37\u20130.98, P = 0.04). Notably, adjusted DFS did not differ significantly (P = 0.96). This discrepancy was driven by distinct recurrence patterns: distant organ metastasis was significantly lower in the nICT group (10.71%\n                      <jats:italic>vs<\/jats:italic>\n                      . 26.25%, P &amp;lt; 0.01). In exploratory analyses, nICT responders exhibited increased CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration and reduced M2-like macrophages (CD68\n                      <jats:sup>+<\/jats:sup>\n                      HLA-DR\n                      <jats:sup>-<\/jats:sup>\n                      ), suggesting a shift from an immunosuppressive to an immune-activated microenvironment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>nICT provided a significant survival advantage over nCT, primarily by inhibiting distant metastasis rather than preventing local recurrence. This benefit may be attributed to immune microenvironment dynamics, specifically characterized by T-cell activation and macrophage modulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1788756","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:14Z","timestamp":1774506794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Survival benefit and dynamics of CD8+ T cells and tumor-associated macrophages in neoadjuvant immunochemotherapy vs. chemotherapy for locally advanced esophageal squamous cell carcinoma: an IPTW-adjusted real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi","family":"Gan","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr433","article-title":"Esophageal carcinoma advances in treatment results for locally advanced disease: review","volume":"23","author":"Herskovic","year":"2012","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"Bmj"},{"key":"B11","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dote.12540","article-title":"Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis esophagus: Off J Int Soc Dis Esophagus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(01)03203-9","article-title":"Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma","volume":"72","author":"Swanson","year":"2001","journal-title":"Ann Thorac surgery"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"B17","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma","volume":"73","author":"Mandard","year":"1994","journal-title":"Clinicopathol correl Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-tumor pathologic scoring of response to PD-(L)1 blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin Cancer res: an Off J Am Assoc Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann surgery"},{"key":"B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","article-title":"Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer","volume":"12","author":"Rice","year":"2017","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308124","article-title":"Global incidence of oesophageal cancer by histological subtype in 2012","volume":"64","author":"Arnold","year":"2015","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.21037\/atm-21-5381","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Trans Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/annonc\/mdt131","article-title":"Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3647-0","article-title":"Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis","volume":"21","author":"Passot","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2008.11.001","article-title":"Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival","volume":"87","author":"Donahue","year":"2009","journal-title":"Ann Thorac surgery"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3164\/jcbn.12-60","article-title":"Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells","volume":"52","author":"Sakai","year":"2013","journal-title":"J Clin Biochem Nutr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S150350","article-title":"Sites of metastasis and overall survival in esophageal cancer: a population-based study","volume":"9","author":"Wu","year":"2017","journal-title":"Cancer Manage Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13924","article-title":"Optimization of immunotherapy strategies based on spatiotemporal heterogeneity of tumour-associated tissue-resident memory T cells","volume":"175","author":"Shang","year":"2025","journal-title":"Immunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1572","article-title":"A composite decision rule of CD8+ T-cell density in tumor biopsies predicts efficacy in early-stage, immunotherapy trials","volume":"30","author":"Dejardin","year":"2024","journal-title":"Clin Cancer res: an Off J Am Assoc Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00649","article-title":"Quantitative characterization of CD8+ T cell clustering and spatial heterogeneity in solid tumors","volume":"8","author":"Gong","year":"2018","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"100621","DOI":"10.1016\/j.ctarc.2022.100621","article-title":"Similarities between wound re-epithelialization and Metastasis in ESCC and the crucial involvement of macrophages: A review","volume":"32","author":"Chabeli","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e002356","DOI":"10.1136\/jitc-2021-002356","article-title":"Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"J immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"104959","DOI":"10.5306\/wjco.v16.i7.104959","article-title":"Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy","volume":"16","author":"Ma","year":"2025","journal-title":"World J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788756\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:15Z","timestamp":1774506795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1788756\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1788756"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1788756","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1788756"}}